Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NFκB2/p100 is a key factor for endotoxin tolerance in human monocytes: a demonstration using primary human monocytes from patients with sepsis.
Cubillos-Zapata C, Hernández-Jiménez E, Toledano V, Esteban-Burgos L, Fernández-Ruíz I, Gómez-Piña V, Del Fresno C, Siliceo M, Prieto-Chinchiña P, Pérez de Diego R, Boscá L, Fresno M, Arnalich F, López-Collazo E. Cubillos-Zapata C, et al. Among authors: esteban burgos l. J Immunol. 2014 Oct 15;193(8):4195-202. doi: 10.4049/jimmunol.1400721. Epub 2014 Sep 15. J Immunol. 2014. PMID: 25225662
Mitochondrial DAMPs induce endotoxin tolerance in human monocytes: an observation in patients with myocardial infarction.
Fernández-Ruiz I, Arnalich F, Cubillos-Zapata C, Hernández-Jiménez E, Moreno-González R, Toledano V, Fernández-Velasco M, Vallejo-Cremades MT, Esteban-Burgos L, de Diego RP, Llamas-Matias MA, García-Arumi E, Martí R, Boscá L, Andreu AL, López-Sendón JL, López-Collazo E. Fernández-Ruiz I, et al. Among authors: esteban burgos l. PLoS One. 2014 May 5;9(5):e95073. doi: 10.1371/journal.pone.0095073. eCollection 2014. PLoS One. 2014. PMID: 24797663 Free PMC article. Clinical Trial.
Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance.
Jurado-Camino T, Córdoba R, Esteban-Burgos L, Hernández-Jiménez E, Toledano V, Hernandez-Rivas JA, Ruiz-Sainz E, Cobo T, Siliceo M, Perez de Diego R, Belda C, Cubillos-Zapata C, López-Collazo E. Jurado-Camino T, et al. Among authors: esteban burgos l. J Immunol. 2015 Jan 15;194(2):719-27. doi: 10.4049/jimmunol.1402272. Epub 2014 Dec 10. J Immunol. 2015. PMID: 25505275 Clinical Trial.
A Braf kinase-inactive mutant induces lung adenocarcinoma.
Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D. Nieto P, et al. Among authors: esteban burgos l. Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2. Nature. 2017. PMID: 28783725 Free PMC article.
c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.
Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M. Sanclemente M, et al. Among authors: esteban burgos l. Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27. Cancer Cell. 2018. PMID: 29395869 Free article.
Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M. Esteban-Burgos L, et al. Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24415-24426. doi: 10.1073/pnas.2002520117. Epub 2020 Sep 10. Proc Natl Acad Sci U S A. 2020. PMID: 32913049 Free PMC article.
RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.
Sanclemente M, Nieto P, Garcia-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, Drosten M, Caleiras E, Martinez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M. Sanclemente M, et al. Among authors: esteban burgos l. Cancer Cell. 2021 Mar 8;39(3):294-296. doi: 10.1016/j.ccell.2021.01.008. Epub 2021 Jan 28. Cancer Cell. 2021. PMID: 33513349 Free article. No abstract available.
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li J, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob HKC, Cabras L, Musteanu M, Drosten M, Ortega S, Mulero F, Sainz B Jr, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M. Blasco MT, et al. Among authors: esteban burgos l. Cancer Cell. 2019 Apr 15;35(4):573-587.e6. doi: 10.1016/j.ccell.2019.03.002. Epub 2019 Apr 8. Cancer Cell. 2019. PMID: 30975481 Free PMC article.
Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors.
Fernández-García F, Fernández-Rodríguez A, Fustero-Torre C, Piñeiro-Yáñez E, Wang H, Lechuga CG, Callejas S, Álvarez R, López-García A, Esteban-Burgos L, Salmón M, San Román M, Guerra C, Ambrogio C, Drosten M, Santamaría D, Al-Shahrour F, Dopazo A, Barbacid M, Musteanu M. Fernández-García F, et al. Among authors: esteban burgos l. Proc Natl Acad Sci U S A. 2024 Sep 3;121(36):e2402913121. doi: 10.1073/pnas.2402913121. Epub 2024 Aug 26. Proc Natl Acad Sci U S A. 2024. PMID: 39186651